Dr Reddys Laboratories (RDY) Non-Current Receivables (2017 - 2025)
Dr Reddys Laboratories (RDY) has 8 years of Non-Current Receivables data on record, last reported at $44.8 million in Q1 2024.
- For Q1 2024, Non-Current Receivables rose 36.97% year-over-year to $44.8 million; the TTM value through Mar 2024 reached $44.8 million, up 36.97%, while the annual FY2024 figure was $44.9 million, N/A changed from the prior year.
- Non-Current Receivables reached $44.8 million in Q1 2024 per RDY's latest filing, up from $32.7 million in the prior quarter.
- Across five years, Non-Current Receivables topped out at $44.8 million in Q1 2024 and bottomed at $718150.0 in Q1 2022.
- Average Non-Current Receivables over 5 years is $20.8 million, with a median of $24.0 million recorded in 2020.
- Peak YoY movement for Non-Current Receivables: crashed 93.25% in 2021, then surged 4451.55% in 2023.
- A 5-year view of Non-Current Receivables shows it stood at $24.0 million in 2020, then plummeted by 93.25% to $1.6 million in 2021, then plummeted by 55.62% to $718150.0 in 2022, then soared by 4451.55% to $32.7 million in 2023, then skyrocketed by 36.97% to $44.8 million in 2024.
- Per Business Quant database, its latest 3 readings for Non-Current Receivables were $44.8 million in Q1 2024, $32.7 million in Q1 2023, and $718150.0 in Q1 2022.